Literature DB >> 9715604

Seizures following chloroquine treatment of type II lepra reaction: a case report.

B E Ebenso1.   

Abstract

A case of tonic-clonic seizures following chloroquine treatment for leprosy reactions in a Nigerian male is reported. Seizures were controlled with phenytoin sodium capsules. A casual relationship between the seizures and chloroquine is suggested. There have been no previous reports of this adverse reaction in leprosy patients receiving chloroquine for treatment of reactions. The author recommends that chloroquine be used with caution especially in patients with seizures.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9715604     DOI: 10.5935/0305-7518.19980021

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  4 in total

1.  Seizure associated with chloroquine therapy in a patient with systemic lupus erythematosus.

Authors:  Antonio G Tristano; Luz Falcón; María Willson; Ivette Montes de Oca
Journal:  Rheumatol Int       Date:  2004-01-23       Impact factor: 2.631

Review 2.  Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.

Authors:  Sergio Marin; Alba Martin Val; Maite Bosch Peligero; Cristina Rodríguez-Bernuz; Ariadna Pérez-Ricart; Laia Vilaró Jaques; Roger Paredes; Josep Roca; Carles Quiñones
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-21

3.  Chloroquine-induced bilateral anterior shoulder dislocation: a unique aetiology for a rare clinical problem.

Authors:  Alexander Nicholas Martin; Dimitris Tsekes; William James White; Dan Rossouw
Journal:  BMJ Case Rep       Date:  2016-03-22

4.  Seizures as a rare adverse effect of chloroquine therapy in systemic lupus erythematosus patients: a case report and literature survey.

Authors:  Piotr Krzeminski; Aleksandra Lesiak; Joanna Narbutt
Journal:  Postepy Dermatol Alergol       Date:  2018-08-21       Impact factor: 1.837

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.